These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 34321318)

  • 1. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS.
    Coyne AN; Baskerville V; Zaepfel BL; Dickson DW; Rigo F; Bennett F; Lusk CP; Rothstein JD
    Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUN1 facilitates CHMP7 nuclear influx and injury cascades in sporadic amyotrophic lateral sclerosis.
    Baskerville V; Rapuri S; Mehlhop E; Coyne AN
    Brain; 2024 Jan; 147(1):109-121. PubMed ID: 37639327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ESCRT-III protein VPS4, but not CHMP4B or CHMP2B, is pathologically increased in familial and sporadic ALS neuronal nuclei.
    Coyne AN; Rothstein JD
    Acta Neuropathol Commun; 2021 Jul; 9(1):127. PubMed ID: 34281622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G
    Coyne AN; Zaepfel BL; Hayes L; Fitchman B; Salzberg Y; Luo EC; Bowen K; Trost H; Aigner S; Rigo F; Yeo GW; Harel A; Svendsen CN; Sareen D; Rothstein JD
    Neuron; 2020 Sep; 107(6):1124-1140.e11. PubMed ID: 32673563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD.
    Chou CC; Zhang Y; Umoh ME; Vaughan SW; Lorenzini I; Liu F; Sayegh M; Donlin-Asp PG; Chen YH; Duong DM; Seyfried NT; Powers MA; Kukar T; Hales CM; Gearing M; Cairns NJ; Boylan KB; Dickson DW; Rademakers R; Zhang YJ; Petrucelli L; Sattler R; Zarnescu DC; Glass JD; Rossoll W
    Nat Neurosci; 2018 Feb; 21(2):228-239. PubMed ID: 29311743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility.
    Gleixner AM; Verdone BM; Otte CG; Anderson EN; Ramesh N; Shapiro OR; Gale JR; Mauna JC; Mann JR; Copley KE; Daley EL; Ortega JA; Cicardi ME; Kiskinis E; Kofler J; Pandey UB; Trotti D; Donnelly CJ
    Nat Commun; 2022 Jun; 13(1):3380. PubMed ID: 35697676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels.
    Beckers J; Tharkeshwar AK; Van Damme P
    Autophagy; 2021 Nov; 17(11):3306-3322. PubMed ID: 33632058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPSNs.
    Rothstein JD; Warlick C; Coyne AN
    bioRxiv; 2023 Dec; ():. PubMed ID: 38168312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC complex alterations are a key feature of sporadic and familial ALS/FTD.
    Sirtori R; J Gregoire M; M Potts E; Collins A; Donatelli L; Fallini C
    Acta Neuropathol Commun; 2024 Apr; 12(1):69. PubMed ID: 38664831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Connections between Nuclear Pore Complex Homeostasis and ALS.
    Chandra S; Lusk CP
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.
    Moore S; Alsop E; Lorenzini I; Starr A; Rabichow BE; Mendez E; Levy JL; Burciu C; Reiman R; Chew J; Belzil VV; W Dickson D; Robertson J; Staats KA; Ichida JK; Petrucelli L; Van Keuren-Jensen K; Sattler R
    Acta Neuropathol; 2019 Jul; 138(1):49-65. PubMed ID: 30945056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy.
    Khalil B; Chhangani D; Wren MC; Smith CL; Lee JH; Li X; Puttinger C; Tsai CW; Fortin G; Morderer D; Gao J; Liu F; Lim CK; Chen J; Chou CC; Croft CL; Gleixner AM; Donnelly CJ; Golde TE; Petrucelli L; Oskarsson B; Dickson DW; Zhang K; Shorter J; Yoshimura SH; Barmada SJ; Rincon-Limas DE; Rossoll W
    Mol Neurodegener; 2022 Dec; 17(1):80. PubMed ID: 36482422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSM12-EPAC1 defines a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient.
    Lee J; Park J; Kim JH; Lee G; Park TE; Yoon KJ; Kim YK; Lim C
    PLoS Biol; 2020 Dec; 18(12):e3001002. PubMed ID: 33362237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
    Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
    Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway.
    Ciura S; Sellier C; Campanari ML; Charlet-Berguerand N; Kabashi E
    Autophagy; 2016 Aug; 12(8):1406-8. PubMed ID: 27245636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the impact of disrupted nucleocytoplasmic transport systems in
    McGoldrick P; Robertson J
    Front Cell Neurosci; 2023; 17():1247297. PubMed ID: 37720544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
    Dafinca R; Scaber J; Ababneh N; Lalic T; Weir G; Christian H; Vowles J; Douglas AG; Fletcher-Jones A; Browne C; Nakanishi M; Turner MR; Wade-Martins R; Cowley SA; Talbot K
    Stem Cells; 2016 Aug; 34(8):2063-78. PubMed ID: 27097283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.
    Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA
    Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptic exon detection and transcriptomic changes revealed in single-nuclei RNA sequencing of C9ORF72 patients spanning the ALS-FTD spectrum.
    Gittings LM; Alsop EB; Antone J; Singer M; Whitsett TG; Sattler R; Van Keuren-Jensen K
    Acta Neuropathol; 2023 Sep; 146(3):433-450. PubMed ID: 37466726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain.
    Umoh ME; Dammer EB; Dai J; Duong DM; Lah JJ; Levey AI; Gearing M; Glass JD; Seyfried NT
    EMBO Mol Med; 2018 Jan; 10(1):48-62. PubMed ID: 29191947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.